EXOC6

Across TCGA pan-cancer cohorts, EXOC6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EXOC6 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher EXOC6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EXOC6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

THYM, UCEC, and COAD are the cancer types where EXOC6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	All	0.942	0.617	.013	12	view →
COAD	OS	Median	III,IV	0.221	0.782	.013	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	III,IV	0.740	0.378	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EXOC6–THYM (OS)

Open the THYM breakdown →